{"entity":{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","aka":[],"tldr":"Clarity Pharmaceuticals, a Sydney radiopharmaceutical company, pairs copper isotopes with SAR-bisPSMA, a molecule that binds PSMA on prostate cancer cells: copper-64 for PET imaging, in the phase 3 AMPLIFY and CLARIFY trials, and copper-67 for therapy in the SECuRE trial. The copper-67 therapy is still at the dose-finding stage.","summary":"Co-PSMA head-to-head data (EAU 2026) showed Cu-64 SAR-bisPSMA more than doubled lesion and patient detection versus Ga-68 PSMA-11; FDA Fast Track in biochemical recurrence; commercial manufacturing agreement with Nucleus RadioPharma (April 2026). SECuRE therapy trial: 7 of 19 patients at 8 GBq 67Cu reached complete response or undetectable disease (July 2026).","asOf":"2026-09-04","links":[{"label":"SECuRE update","url":"https://www.prnewswire.com/news-releases/clarity-pharmaceuticals-announces-secure-trial-update-on-8-gbq-67cu-sar-bispsma-dose-level-with-two-additional-complete-responses-302843184.html"}],"tags":[],"related":["ga-68","cu-64","cu-67"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["theranostics"],"trials":["nct04868604"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Sydney","country":"AU","companyType":"radiopharma","website":"https://www.claritypharmaceuticals.com","ticker":"CU6.AX","investors":[],"funding":[]},"route":"/companies/clarity-pharmaceuticals/","neighbours":{"isotope":[{"id":"cu-64","kind":"isotope","name":"Copper-64","route":"/isotopes/cu-64/"},{"id":"cu-67","kind":"isotope","name":"Copper-67","route":"/isotopes/cu-67/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"term":[{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/"}],"trial":[{"id":"nct04868604","kind":"trial","name":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","route":"/trials/nct04868604/"}],"drug":[{"id":"cu-64-sar-bispsma","kind":"drug","name":"Copper-64 SAR-bisPSMA","route":"/drugs/cu-64-sar-bispsma/"}],"company":[{"id":"nuclidium","kind":"company","name":"Nuclidium","route":"/companies/nuclidium/"}]}}